SIRT6 and colorectal carcinoma: Our study discovered a potent and selective activator of SIRT6, MDL-811, which exhibited strong antiproliferative efficacy against CRC in multiple cell-based assays (CRC cell lines and PDOs) and in vivo models (CDX, PDX, and APCmin/+ models).